Ongoing research projects

​HUCS Department of Oncology conducts research on a broad scale, to promote the treatment of cancer and develop medication. All ongoing trials welcome volunteers as participants. An updated list of research projects is available on the Nordic NECT website.

If you are interested and want to know more about the ongoing trials, please contact the ward head nurse, tel. 050 427 0680.

Cancer Research
​​Breast Cancer ​A phase 1B study to evaluate safety anf clinical activity of pembrolozumab (MK-3475) in combination with chemotherapy as neoadjuvant treatment for trible negative breast cancer
​Breast Cancer ​A randomized phase III study comparing trastuzumap, pertuzumab plus docetaxel (TPD) followed by 3 cycles of chemotherapy  to the current standard regimen as the treatments of early HER2-positive breast cancer
​Breast Cancer ​A Phase II randomized, douple-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breats cancr subjects with bone metastases treated with hormonl treatment background therapy
​Breast Cancer

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who have received two prior Anti-HER2 therapies and require systemic treatment

​Esophagus Cancer ​A phase III randomized open-label study of single agent pembrolizumab vs physicians' choise of single agent docetaxel, paclitaxel or irinotecan in subjects with advanced/metastatic adenocarcinoma and squamous cell carcinoma of the esophagus that have progressed after first line standard therapy
Gastric Cancer​ Effects of S-1 and capecitabine in combination with oxaliplatin on the coronary artery blood flow in patients metastatic gastrointestinal tract adenocarcinoma: a randomized phase II study​
Gastrointestinal Cancer Open-label, single-arm, phase II study of bevacizumab in combination with alternating XELIRI and XELOX as first-line treatment of patients with metastatic colorectal  cancer​
​GIST​ ​A randomized phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumor (GIST)
​GIST​ ​Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomized phase III study
​Lymphoma​ ​A phase 1/2 study of combination of pixantrone, etoposide, bendamustine and in CD-20 positive tumors, rituximab in patients with relapsed aggressive non-Hodgkin lymphomas of B- or T- cell phenotype- The PREBEN study
​Lymphoma​ ​Brentuxumab vedotin or B-CAP in treatment of older patients with newly diagnosed classical Hodgkin Lymphoma - a GHSG-NLG Intergroup Phase II- trial
​Lymphoma​ ​A phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL)- CHRonos-4
Lymphoma​ Alemtuzumab and CHOP in T-cell lymphoma (The ACT-1 trial): A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP versus 2-weekly CHOP alone and consolidated by autologous stem cell transplant, in young patients with previously untreated systemic peripheral T-cell lymphomas.​
Lymphoma​ Open-label, uncontrolled phase II trial of intravenous PI3K inhibitor BAY-80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin´s lymphomas​​
Lymphoma​ A comparative, randomoized, parallel-group, multi-centre phase IIIb study to investigate the efficacy of sc rituximab vs iv ritiximab both in combination with CHOP (R-CHOP) in previously untreated patients with CD20 positive diffuse large B-cell lymphoma​​
Lymphoma​ Dose densified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk Diffuse Large B-Cell Lymphoma (NLG-LBC05)​
Lymphoma​ A multicenter phase III, open-label, randomized study in previously untreated patients with advanced indolent Non-hodgkin's lymfphoma evaluating the benefit of GA101 (RO5072759) plus chemotherapy compared with rituximab plus chemotherapy followed by GA101 or rituximamb maintenance therapy in responders​
Lymphoma​ A randomized, douple-blind, placebo-controlled phase 3 -study of the bruton´s tyrosine kinase (bkt) inhibitor, pci-32765 (ibrutinib), in combination with rituximab, cyclophosphamide, doxorubisin, vincristine and prednisone (r-chop) in subjects with newly diagnosed non- germinal subtype of diffuse large b-cell lymphoma​​
​Melanoma​​ ​Adjuvant immunotherapy with anti-PD-1  monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trail on the EORTC Melanoma Group
​Melanoma​​ ​A phase 3, randomized, double-blind study of adjuvant immunotherapy with nivolumb verus ipilimumab after complete resection of stage IIIB/C or stage IV melanoma in subjects who are at high risk for recurrence
​Melanoma​​ ​The Melanoma Group Trial: TOL+ vemurafenib followed by interferon + vemurafenib maintenance (BRAF- positive patents) or TOL followed by interferon maintenance (BRAF-negative patients)
​Pancreatic Cancer​ ​A phase 3, multicenter, open-label, randomized study of nab-paclitaxel plus gemcitabine versus gemcitabine alone as adjuvant therapy in subjects with surgically resected pancreatic adenocarcinoma "apact"
​Prostate Cancer​ ​Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer (DUALIDES)
​Rectum Cancer ​A phase III study pf pembrolizumab (MK-3475-177 MCRC) vs chemotherapy in microsatelliet instability-high (MSH-H) or mismatch repair deficient (dMMR) stage IV colorectal carsinoma
​Rectum Cancer ​Full dose monotherapy S-1 (followed by irinotecan) compared to reduced dose combination therapy (S-1/pxaliplatin followed by S-1/irinotecan) as initilal therapy for older patients with metastatic colorectal cancer
​​Renal Cancer ​A phase 3, randomized, open-label study of nivolumab combined with ibilimumab versus sunitinib monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma
​Renal Cancer ​CA209-214 A phase 3, randomized, open-label study of nivolumab combined with ibilimumab versus sunitinib monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma
​Solid Tumor ​A phase 1/2 study of safety and efficacy of ulocuplumab combined with nivolumab in subjects with advanced or metastatic solid tumors
​Solid Tumor ​An open label, multicohort, phase II study of MPDL3280A in advanced solid tumors
​Solid Tumor​​ ​An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification
Solid Tumor Safety and pharmacokinetics of ODM-207 in patienst with selected advanced tumors; an open-label, non-randomosed, uncontrolled, multicentre, first-in-human study with cohort expansion
Solid Tumor​​ CA209-032 A Phase 1/2 open-label study of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic solid tumors​​
​Solid Tumor​​ ​Safety and tolerability of single and repeated doses of ODM-203: an opel-label, non-randomized, uncontrolled, dose escalation, multicentre, first-in-human study in subjects with advanced solid tumors
Thyroid ​Cancer​ ​Reduction in radioiodine treatments in low risk papillary thyroid cancer
​Urinary Tract Cancer ​A phase II single arm clinical trial of nivolumab (BMS936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agent